This systematic review aimed to analyze the efficacy of corticosteroid premedication compared to placebo or no treatment to reduce postoperative pain in endodontic patients. Randomized controlled trials (RCTs) assessing corticosteroids via oral, intramuscular, subperiosteal, intraligamentary or intracanal route compared to passive or active placebo, or no treatment were included. Four databases were searched: PubMed, Web of Science, Cochrane Library and Embase up to 2/21/2018. Risk of bias was assessed with Cochrane Risk of bias tool. Fourteen RCTs with 1,462 generally healthy adults in need of endodontic treatment were included. 50% of the studies were at unclear risk and 50% at high risk of bias. Meta-analysis showed Visual Analog Scale (VAS) pain at 4-6 hours after Inferior Alveolar Nerve Block (IANB) was significantly lower by 21 points (0-100 scale) in the corticosteroid group compared to the control group (95% CI -35 to -7; P = 0.003), however this difference was not statistically significant after 24 hours (P = 0.116). The route of administration was oral and intraligament injection. Patients who received corticosteroids prior to IANB were 70.7% more likely to have none or mild pain 4-8 hours after treatment (P = 0.001) and 13.5% more likely 24 hours after IANB (P = 0.013) than patients in the control group. In conclusion, corticosteroid administration (oral or intraligamental) may clinically reduce the level of postoperative pain at 4-8 hours after IANB, however the quality of the evidence was low/moderate due to risk of bias and heterogeneity. Further studies are recommended.
INTRODUCTION
The International Association for the Study of Pain [1] in 1994, has defined pain as an "unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage" [1] . The complex mechanisms of pain are still being actively researched and elucidated [2] . The incidence of significant postoperative pain in endodontic patients is reported to be between 3-58% [3] . The wide variation can be linked to differences in study design, technique protocol, pain measurement, operator experience, and pre-existing mitigating factors such as inflammation and infection [2] . Pain origin associated with endodontic therapy primarily includes bacterial (either from an abscess, or introduced during treatment, swelling, instrumentation), chemical (irrigants/intracanal medication) or hyper-occlusion [4] .
For reduction of pain during endodontic therapy clinicians employ diverse non-pharmacologic measures such as occlusal reduction, incision and drainage, trephination, careful extirpation, cleaning and obturation, as well as non-traditional measures such as hypnosis [5] . However, to control and minimize the post-operative pain, analgesics (over the counter, or prescribed), opioids or corticosteroids may be required [6] . The use of a corticosteroid to reduce pre-operative, intra-operative and post-operative endodontic pain was described as early as 1956 by Stewart [7] . There are no conclusive guidelines on the ideal route of administration or the corticosteroid of choice. A prior literature review recommends that the steroid be delivered at least a few hours prior to treatment [8] .
Pharmacodynamics of drugs are complex, having its effect at the receptor level in cell membranes, in the mitochondria, and nuclei [9] . Though the underlying mechanism of endodontic pain is inflammation, a complex interaction of gene activation and repression results through the nucleus anti-inflammatory proteins [10] . Corticosteroids affect these genes rapidly and profoundly [11] . Additionally, cell injury results in the release of arachidonic acid from cell membranes and metabolized by multiple pathways to a variety of prostanoids (including prostaglandins and thromboxane A2) [12] . This resultant inflammatory milieu can activate or sensitize peripheral nociceptors (free ending pain receptors) [9] .
In clinical practice, dentists target two cyclooxygenase (COX) isoforms, COX-1 and COX-2. The nonsteroidal anti-inflammatory drug (NSAID) acts as competitive active site inhibitors of these COXs resulting in blocking them selectively or non-selectively. However, they have no effect on the other mediator: leukotrienes. Corticosteroids have multiple sites of action and are potent inhibitors of both pathways because they inhibit the enzyme phospholipase [4] . Glucocorticoids are similar in structure and clinical effects. The potency, duration and salt retaining activity are the primary differences [13] . 
MATERIALS AND METHODS
The clinical PICOS question to be answered was as follows: in adult patients in need of non-surgical initial endodontic treatment (population), does the systemic or local administration of corticosteroids (intervention) reduce intensity of postoperative endodontic pain (outcome) compared to a passive placebo, active placebo or no treatment? The setting was private dental clinic, dental school or university hospital.
Inclusion and exclusion criteria. Studies were limited to randomized controlled trials (RCTs) on the efficacy of intramuscular, supraperiosteal, intraligamentary injection, intracanal or systemic use of corticosteroids to reduce postoperative endodontic pain. Opinion papers, editorials/commentaries, literature reviews, systematic reviews, case studies, animal studies, and clinical guidelines were excluded, however literature reviews, systematic reviews and clinical guidelines were scanned for relevant trials. The database search was conducted again on 3/1/2018 and two relevant studies were found [14, 15] and a recent systematic review [16] . [17] . A risk of bias followed for summary of the review findings and quality of evidence assessment using the software, GRADE profiler© (Grader©) [17] . Of those 45 references, fourteen were eligible to be included in qualitative analyses [14, 15, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . The reasons for exclusion after full-text were that the intervention was a combination of corticosteroid and antibiotic (n = 8), no endodontic treatment (n = 7), no corticosteroid (n = 8), no pain outcome (n = 1), no post-endodontic pain outcome -pain during anesthesia (n = 1) [32] , no control group (n = 1), different intervention (n = 3), no placebo/no treatment group (n = 1) and a review/systematic review of the literature (n = 1). PRISMA flowchart shows a summary of our results (Fig. 1 ). Population. Patients were a mix of symptomatic, asymptomatic or both with a total of 1,462 participants.
Selection of Studies and Data
All patients needed non-surgical initial endodontic treatment. The majority of included studies were held in endodontics department of dental schools, except one which was done in a private practice [28] and two articles did not specify their clinical set up [27, 32, 33] .
Four studies [20, 23, 27, 31] [24] Endodontic patients undergoing endodontic treatment.
No discussion about possible side effects
Elkhadem et al. 2017 [14] Symptomatic irreversible pulpitis diagnosis; Pulp sensitivity was confimed by positive response to electric pulp test and prolonged exaggerated response with moderate-to-severe pain to a cold test.
The patients receiving interventions recorded no adverse effects.
Glassman et al.
1989 [25] Patients requiring non-surgical endodontic therapy; Asymptomatic vital-inflamed teeth without evidence of periapical radiolucent lesions.
No discussion about possible side effects Jalalzadeh et al. 2010 [26] Requirement for nonsurgical endodontic therapy in single or multi-root teeth (premolar and molar); Vital and non-vital pulp and asymptomatic and symptomatic teeth were included.
No side effects were reported for any of the medications used.
Kaufman et al. 1994 [27] ASA category I or II; Required endodontic treatment in any maxillary or mandibulartooth; Teeth could be treated endodontically in one visit (for standardization of independent variables).
No reports of adverse systemic or local tissue reactions to the injected drugs were reported during the interviews. Krasner et al. 1986 [28] Required endodontic treatment on a previously untreated tooth.
Dizziness, stomach upset, swelling of the face, and tachycardia reportedevenly distributed between the dexamethasone and placebo groups. Not severe enough to discontinue the prescribed medication. Liesinger et al. 1993 [29] Preoperative diagnosis of irreversible pulpitis or acute apical periodontitis. There were no reported instances of posttreatment swelling and/or infection by any patient Marshall & Walton, 1984 [30] Presented for conventional root canal therapy.
No discussion about possible side effects Indications for nonsurgical endodontic therapy in single or multi-root teeth and asymptomatic vital inflamed pulps.
No side effects were reported for any of the medications used. Praveen et al. 2017 [15] Pulpal diagnosis of irreversible pulpitis or pulpal necrosis in single-rooted teeth. Rogers et al. 1999 [22] No medical contraindication, between age 18 and 65, no pregnant or nursing, no history of peptic ulcer or GI bleeding, not hypersensitivity or allergic to NSAIDS or corticosteroids, not at risk for renal failure or renal impairment, no radiographic evidence of periapical pathosis; Only patients with a vital pulp (either diagnosed as an irreversible pulpitis or normal, but in need of endodontic therapy as determined by an electric tester and thermal tester).
Shantiaee et al. 2012 [23] ASA I or II, required endodontic treatment in upper or lower molar teeth, had no history of root canal therapy. < 10% of patients in dexamethasone group experienced dizziness. [21, 22, 25, 26, 30] . The gender and age of the study groups is listed in Table 1 . Eight studies specified their gender ratio of their samples and F/M ratio varied from 0.9 to 2.3 [14, 15, 20, 21, 23, 26, 27, 31] with a majority of females in most of the studies. The age of the participants was between 18 to 71 ( Table 1 ). The final number of participants in each study ranged in size from 40 [26] to 400 [14] .
Thermal test was the most common diagnostic tool to assess the pulp vitality [14, 20, 22, 24, 26] , some of the studies used electrical pulp test (EPT) [14, 22, 24] . In some studies, pulp vitality was an important inclusion criteria [21, 22, 25, 31] but two studies included both vital and non-vital teeth in their intervention group [15, 26] . Two studies included only asymptomatic irreversible pulpitis [21, 25] while two studies did the opposite and only included symptomatic irreversible pulpitis [14, 20] .
Amongst included studies, one study had the most periodontitis, acute or chronic apical abscess). The presence of pre-operative pain was specified in three studies [29, 31] and the absence of pain in one study [25] ( Table 2 ). The remainder allowed both. The teeth treated varied across studies from any premolar/molar [26] , upper or lower incisor or premolar [31] , any molar [20, 23] , single rooted tooth [21] , to any tooth needing endodontic treatment [21, 22, 27, 28, 30] , and three studies made no mention of specific teeth [24, 25, 29] . The intervention was a corticosteroid (dexamethasone in nine studies [20] [21] [22] [23] 25, [28] [29] [30] [31] , prednisolone in four studies [14, 15, 24, 26] , and a single study used methylprednisolone [27] . Some studies evaluated other single drug interventions besides the corticosteroid (ketorolac [22] , ibuprofen [22] , morphine [23] ). The local anesthetic used for obtaining operative anesthesia was only mentioned in six studies: 2% lidocaine with 1:100,000 epinephrine [15, 21, 26] , 1:80,000 epinephrine [20] or 2% mepivacaine with 1:100,000 epi [20] and Mepecaine-L [14] (Table 1) .
Comparison: Control groups included passive placebos (saline, glucose, dextrose gelatine), active placebo (2% lidocaine) in one study [31] or no treatment [27] . The only study with an active placebo group (2% lidocaine) but no passive placebo [31] was excluded of the meta-analysis to reduce heterogeneity (Table 1) . 
Outcomes

Risk of bias in included studies
Summaries of risk of bias for each domain are shown in Table 3 (Summary of risk of bias for eligible studies) and Fig. 2 (Graph of risk of bias for eligible studies) [14, 15, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] .
Random Sequence Generation. Eleven of the studies [ [20] [21] [22] [23] [24] [25] [26] [28] [29] [30] [31] were classified as unclear risk of bias because they gave no description of the method or methods used to generate the random sequence in their studies. In three studies [14, 15, 27 ] the methods of sequence generation were stated as computer-generated or using a permuted block randomization method along with an internet-based random number generator [14] , and were assigned a low risk of bias in this area.
Allocation Concealment. The allocation of the participants in ten of the studies [14, 15, 20, 21, [23] [24] [25] [26] [28] [29] [30] [31] was low risk because, they were dispensed in disposable syringes, vials, tablets with numeric coding (by second investigator not involved in study) for treatment sequence. However it was unclear in one study where the authors claimed the study was double-blinded, but no details were provided as how the allocation was concealed [27] , while in one study it was considered high risk [22] , where there were no details of how the treatment groups were concealed nor any blinding strategies.
Blinding. Blinding was high risk in one study as no blinding method was described [22] . Blinding was assessed as unclear risk in eleven of the studies [14, 15, 20, 21, [23] [24] [25] [26] [27] [28] [29] [30] [31] . In each of these studies the blinding of the data analyst and technique of blinding were not described which could have resulted in bias.
Incomplete outcome data. In this category, six studies [14, 15, 20, [22] [23] [24] had low risk of bias since the number of drop outs were minimal, intent-to-treat analysis was provided if needed and reasons for dropping out were balanced among treatment group. Six studies [21, 25, [27] [28] [29] 31] fell into the category of unclear risk due to lack of intent-to-treat analysis [21, 27, 29] , excluded patients due to severe pain or rescue medication [25] , unclear number of excluded patients due to rescue medication [31] , or total number of patients enrolled and excluded was not fully disclosed [29] or the reason for missing data were not fully disclosed [27] .Two studies were considered at high risk due to the high number of patient's exclusions (>20%) [26] or the unclear description of which intervention did the participants received before reporting their pain [30] .
Selective reporting. In this domain, eleven articles [14, 15, [20] [21] [22] [23] [24] [25] [27] [28] [29] [30] [31] were considered as low risk since they reported all pre-specified outcomes. One article [26] is high risk. In this article, the large numbers of excluded patients due to usage rescue medications (41% in placebo group, 31% in medication group) were not fully addressed so it is considered as high risk of bias.
Other bias. We considered six studies [14, 24, 25, 27, 28, 31] with unclear risk of other bias due to non-disclosure of their source of funding or co-interventions (i.e. parachlorophenol [24] ). Four studies were at high risk of other bias due to rescue medications [21] [22] [23] 29] , occlusion adjustment [26] or lidocaine [20] .
Balanced groups at baseline:
The studies that did not report age and gender distribution were considered as unclear risk of bias [22, [24] [25] [26] [27] [28] [29] [30] [31] . The ones which had balanced groups at baseline for age, gender or the intensity of pre-treatment pain were considered low risk [15, 20, 21, 23] .
Overall bias. A total of 50% of the studies were assessed at unclear risk of bias and 50% at high risk (Table 3 , Fig. 2 ).
Effects of interventions
Fourteen studies were included in this review, however only nine studies could be included in the meta-analyses. to control at 12 hours after IANB (random-effects model:
Difference in means = -19.629; 95% CI = -37.069 to -2.190; P = 0.027) (Fig. 4B) .
Subgroup analysis by type of corticosteroids: VAS pain
after IANB was decreased but not significantly with dexamethasone in two studies (P = 0.105) and methylprednisone (P = 0.173), however the lack of statistical significance might be due to the small number of studies.
Oral prednisolone decreased significantly postoperatively 4-6 hours after IANB with three studies (P = 0.009) (Fig. 5) .
Likelihood of none or mild post-treatment pain:
Patients who received corticosteroids prior to IANB were 70.7% more likely to have none or mild pain at 4-8 hours post-treatment (random effects model: RR = 1.707; 95% CI = 1.234 to 2.363; P = 0.001) than controls (Fig. 6A ).
At 24 hours post-treatment, the results were still favorable to corticosteroids with 13.5% more likely to have none or mild pain (fixed-effect model: RR = 1.135; 95% CI = 1.027 to 1.255; P = 0.013) (Fig. 6B) .
Symptomatic, asymptomatic patients or both:
Subgroup analyses by type of patient included in the studies found similar results. Patients in the corticosteroids groups were 50% more likely to have none or mild pain compared to controls in symptomatic patients in one study at high risk [25] ; 71.3% more likely in four studies including both, symptomatic and asymptomatic patients; and 48.3% more likely in one study with only asymptomatic patients (P = 0.003) [31] .
Adverse effects
Only one study reported a distinctive side effect of dizziness in less than 10% of its patients who took dexamethasone [23] . Very few side effects were reported by the subjects in another study, and these were evenly distributed between the dexamethasone and placebo groups. These effects were dizziness, stomach upset, corticosteroid group (from 19 more to 180 more) compared to control group at 24 hrs. CI: Confidence interval; RR: Risk ratio; N/A: Not applicable GRADE Working Group grades of evidenceHigh certainty:We are very confident that the true effect lies close to that of the estimate of the effect; Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; Low certainty:Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect; Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect a Unclear or high risk of bias in all studies, b Statistically significant heterogeneity (P < 0.10) and I 2 larger than 50%. swelling of the face, and tachycardia. This might not be related to the corticosteroid as it happened in both groups [28] ( Table 2 ).
Summary of the evidence and quality of the findings (GRADE)
The quality of the evidence was low for all outcomes except one due to unclear/high risk of bias and statistically significant heterogeneity (Q p-value < .10 and I 2 larger than 50%); low evidence grading indicates that further research is very likely to have an important impact on our confidence in the estimate of effect and it is likely to change the estimate. One meta-analysis -none or mild pain at 24 hours -did not suffer of statistical heterogeneity and was assessed at moderate quality of evidence (Table 4) . 
Heterogeneity of the review
The vast clinical heterogeneity amongst the 1,462 en- However, further studies on this are needed.
Half-life elimination of oral dexamethasone in adults is 4 ± 0.9 hours with time to peak in serum about 1-2 hours [35] . For methylprednisolone, the half-life elimination is 2.5 ± 1.2 hours with time to peak in serum around 2.1 ± 0.7 hours [35] . In regards to oral prednisolone, half-life elimination is 2-4 hours and time to peak in serum is 1-2 hours [35] . It is important to consider the pharmacokinetics of corticosteroid medications in their efficacy of reducing post-operative pain. [35] The medications that were mostly used in our included studies Although the time of drug administration was clearly specified in each study as either before, at the time of the procedure, right after (with or without continuing taking the medication), it is unclear when was the postoperative follow up time reference (i.e. just after local anesthetic was delivered or after surgery), which adds to the heterogeneity of the outcome data and difficulty in results comparison.
Agreements and disagreements with other studies or reviews
In the Compendium of Continuing Education Dental, Patten et al. 1992 reported that short term use of dexamethasone enables the clinician to take advantage of its anti-inflammatory properties and thus, dexamethasone can be an effective adjunct for postoperative control of dental pain [36] . Mohammadi [37] In that review, all meta-analyses revealed a statistically significant difference favorable to the dexamethasone groups at 8 hrs (RR = 1.97, P < 0.05), 12 hrs (RR = 2.54, P < 0.05), and 24 hrs (RR = 2.58, P < 0.05). Both, the single blinded study and not blinded were excluded of the meta-analyses to decrease bias. Thereby, the overall strength of the evidence (according to the GRADE system [17] ) was low owing to unclear/high risk of bias, and statistical heterogeneity or moderate for only one outcome. The authors recommend well designed randomized, controlled, double masked trials to provide appropriate guidelines to clinicians.
Overall completeness, applicability and quality of the evidence
Implications for research and clinical practice
In acute postoperative pain, various mechanisms are involved including deregulation of the inflammatory process, pain amplification and affected central inhibitory control [39] . Further central sensitization and hyperalgesia occurs due to continued pathological endodontic stimuli. Wind-up pain hyperalgesia can be an important factor during endodontic therapy due to these repeated stimulus frequencies resulting in enhancement of host cellular responses in magnitude and duration [40] . This were not discussed either and should be looked into.
CONCLUSIONS
Our meta-analysis shows evidence of significant impact of using corticosteroid on postoperative pain reduction at 4-6 hours and 12 hours following endodontic treatment on a tooth. However, these studies could not demonstrate any remarkable effect of reducing postoperative pain at 24 hours period. We also can point out the corticosteroid effect on increasing the success rate of IANB injection, but we have to be cautious with our conclusions due to statistical heterogeneity in some analyses and unclear/ high risk of bias. It is worth noting that the most common form of corticosteroid used in our included studies was oral administration of dexamethasone. Because of high risk of bias and great heterogeneity of clinical data, the authors call for more quality double blinded studies in the future to further shining light on efficacy of corticosteroid usage for pain reduction in endodontic treatment.
